Roche On The Wrong Side For Once In Shifting Analyst Forecasts
EP Vantage - Seeking Alpha - Sat Jun 06, 7:32AM CDT
Roche 's ( OTCPK:RHHBF ) ( OTCQX:RHHBY ) reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. On the...
SGYP: 6.32 (+0.18), VRTX: 110.00 (+0.97), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), IBB: 308.45 (+1.25), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
The Battle Of The Bulge
The Nattering Naybob - at Seeking Alpha - Mon May 18, 8:59AM CDT
ABT: 41.89 (+0.73), PFE: 33.24 (+0.15), SYY: 40.93 (-0.02), LO: 71.40 (-0.33), LLY: 86.14 (+2.37), MDRX: 12.69 (+0.31), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), MO: 56.81 (+0.44), ATHN: 139.41 (+4.17), PM: 84.07 (-0.08), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AAC: 26.22 (-0.54), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), WTW: 6.90 (-0.41), NVS: 91.90 (-0.71)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 66.69 (-0.19), RBS: 10.21 (-0.01), SPY: 201.33 (+0.12), LYG: 4.80 (+0.03), AV: 14.62 (-0.11), MR: 24.13 (-0.04), PSO: 18.72 (-0.04), LBTYK: 43.26 (-0.02), TI: 12.49 (+0.29), LBTYA: 45.15 (-0.06), BHP: 37.76 (+0.44), TEF: 13.11 (+0.29), DIA: 170.76 (+0.39), ING: 14.44 (-0.18), RIO: 39.74 (+0.93), PHG: 25.62 (+0.36), VOD: 32.32 (-0.09), QQQ: 106.53 (+0.48)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 503.92 (+12.71), NVS: 91.90 (-0.71)
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 32.59 (+0.13), NVS: 91.90 (-0.71)
Flexus Shows Other Immuno-Oncology Wannabes How It's Done
EP Vantage - Seeking Alpha - Wed Feb 25, 1:28PM CST
Deal making in the immuno-oncology space was always going to be a big theme of 2015, and Bristol-Myers Squibb ’s (NYSE: BMY ) moves yesterday – most notably the $800m it paid to secure Flexus Biosciences ’ preclinical...
MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), NLNK: 34.31 (+1.42), BMY: 61.44 (+0.93)
Why Don't You Diversify Your Portfolio With Some European Blue Chips?
Gold Finder - at Seeking Alpha - Fri Jan 23, 9:50AM CST
UN: 42.26 (+0.19), HSBC: 40.57 (-0.22), GOOG: 643.61 (+4.45), T: 33.14 (-0.26), BRK.A: 199,650.00 (-966.00), NVS: 91.90 (-0.71)
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 19.97 (+0.38), AKER: 3.54 (+0.04), WX: 44.15 (+0.04)